Plasma porphyrins among end stage renal disease patients and cutaneous symptoms- is there still an association?

Authors:
Goldman S; Zidan O; Edel Y; Schechter A; Mimouni T and 5 more

Journal:
Mol Genet Metab Rep

Publication Year: 2022

DOI:
10.1016/j.ymgmr.2022.100928

PMCID:
PMC9587357

PMID:
36281443

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Mol Genet Metab Rep

Abbreviation: Mol Genet Metab Rep

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Genetics & Heredity

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A novel <i>GATA3</i> frameshift mutation causes hypoparathyroidism, sensorineural deafness, and ren…
Huang B; Li S; Chai Y and 6 more (2024) - Transparency Score: 3/6
Classic and Atypical Late Infantile Neuronal Ceroid Lipofuscinosis in Latin America: Clinical and G…
Guelbert N; Espitia Segura OM; Amoretti C and 32 more (2024) - Transparency Score: 3/6
Clinical and biochemical phenotypes, genotypes, and long-term outcomes of individuals with galactos…
Almenabawy N; Bahl S; Ostlund AL and 4 more (2024) - Transparency Score: 3/6
Induced pluripotent stem cell-derived hepatocytes reveal TCA cycle disruption and the potential bas…
Mathis D; Koch J; Koller S and 6 more (2024) - Transparency Score: 3/6
Letter to the Editors: Concerning "Hyperleucinosis during infections in maple syrup urine disease p…
Takano C; Ogawa E; Arai-Ichinoi N and 1 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors. The results presented in this paper have not been published previously in whole or part, except in abstract format. Declaration of Competing Interest The authors have no conflicts of interest to declare."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025